Endocrinology & Diabetes
On this page
Pathophysiology and Classification of Endocrine Disorders
A 28-year-old woman presents with polyuria, polydipsia, and a 12 kg weight loss over six weeks. Her random glucose is 24.8 mmol/L, and ketones are 4.2 mmol/L. This clinical picture immediately distinguishes from the more insidious presentation of , where patients often remain asymptomatic for years before diagnosis. Understanding the fundamental pathophysiological distinctions between these conditions-autoimmune β-cell destruction versus progressive insulin resistance-forms the cornerstone of endocrine medicine and directly influences every subsequent management decision.
Type 1 Diabetes: Autoimmune Destruction
- Absolute insulin deficiency from T-cell mediated destruction of pancreatic β-cells
- Autoantibodies present in 85-90%: GAD, IA-2, ZnT8, insulin autoantibodies
- Peak incidence: childhood/adolescence, but 40% diagnosed >30 years (LADA)
- HLA associations: DR3-DQ2 and DR4-DQ8 confer highest risk
- C-peptide: <200 pmol/L confirms absolute deficiency
- Ketosis-prone: DKA risk within hours of insulin omission
Type 2 Diabetes: Progressive Insulin Resistance
- Peripheral insulin resistance + relative β-cell dysfunction
- 80-90% associated with obesity (BMI >30 kg/m²)
- UK prevalence: 4.9 million diagnosed, estimated 1 million undiagnosed
- Pathophysiology: ectopic fat deposition in liver/pancreas → lipotoxicity
- C-peptide preserved initially: typically >600 pmol/L
- NICE NG28 diagnostic thresholds:
- Fasting glucose ≥7.0 mmol/L OR
- HbA1c ≥48 mmol/mol (6.5%) OR
- Random glucose ≥11.1 mmol/L with symptoms
| Feature | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| Onset | Acute (days-weeks) | Insidious (years) |
| Age | Usually <30 (but any age) | Usually >40 (but increasing in youth) |
| BMI | Normal/low | Typically >25 kg/m² |
| Ketosis | Prone (DKA common) | Rare (HHS in severe cases) |
| Autoantibodies | Positive (85-90%) | Negative |
| C-peptide | <200 pmol/L | Usually preserved |
Thyroid Dysfunction: Spectrum of Disorders
encompasses primary hypothyroidism (95% of cases), where TSH >10 mU/L with low free T4 indicates overt disease, while TSH 4-10 mU/L with normal T4 defines subclinical hypothyroidism. Hyperthyroidism (TSH <0.1 mU/L, elevated free T4/T3) requires differentiation between Graves' disease (TSH receptor antibodies positive in 90%) and toxic nodular disease.
📌 Mnemonic - The 4 Ts of Type 1 Presentation: Toilet (polyuria), Thirsty (polydipsia), Tired (fatigue), Thinner (weight loss)
Pathophysiology and Classification of Endocrine Disorders
Natural History and Screening Protocols
The natural history of reveals a critical pre-diagnostic window where microvascular damage accumulates silently. Studies demonstrate that 20% of patients already have retinopathy at diagnosis, indicating 4-7 years of undetected hyperglycemia. This underscores why NICE NG28 mandates systematic screening in high-risk populations and immediate complications screening at diagnosis-not years later.
Progression from Pre-diabetes to Complications
- Pre-diabetes definitions (NICE NG28):
- HbA1c 42-47 mmol/mol (6.0-6.4%)
- Fasting glucose 6.1-6.9 mmol/L
- 5-10% annual progression to diabetes without intervention
- Microvascular complications threshold: chronic exposure >7.0 mmol/L
- Retinopathy: detectable changes after 5 years of hyperglycemia
- Nephropathy: ACR >3 mg/mmol indicates early diabetic kidney disease
- Neuropathy: affects 50% by 10 years post-diagnosis
Screening Protocols per NICE NG28
- Annual HbA1c screening if:
- Age >40 years with BMI >25 kg/m² (>23 kg/m² in South Asian populations)
- First-degree relative with diabetes
- Previous gestational diabetes
- Hypertension, CVD, PCOS, severe mental illness
- Immediate complications screening at Type 2 diagnosis:
- Retinopathy: digital fundoscopy within 3 months
- Nephropathy: ACR and eGFR at diagnosis, then annually
- Foot risk assessment: neuropathy testing with 10g monofilament
- Cardiovascular risk: QRISK3 calculator for primary prevention
details how macrovascular risk accumulates earlier than microvascular damage, with cardiovascular disease causing 50% of deaths in Type 2 diabetes. Statin therapy is indicated for all patients >40 years (NICE CG181), and ACE inhibitors reduce cardiovascular events by 25% in those with albuminuria.
Natural History and Screening Protocols
Evidence-Based Treatment Algorithms
A 52-year-old man newly diagnosed with (HbA1c 76 mmol/mol, BMI 34 kg/m²) requires immediate treatment intensification. NICE NG28 mandates starting metformin alongside lifestyle modification, with a structured escalation pathway if HbA1c targets aren't achieved within 3-6 months. Contrast this with , where immediate multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) are non-negotiable to prevent life-threatening .
Type 1 Diabetes: Insulin Replacement
- Basal-bolus regimen (MDI):
- Basal: insulin glargine/detemir/degludec 0.2-0.4 units/kg/day
- Bolus: rapid-acting (aspart/lispro) 0.4-0.6 units/kg/day, divided pre-meals
- Carbohydrate counting: typically 1 unit per 10g carbohydrate (ratio varies)
- CSII (insulin pump) if HbA1c >69 mmol/mol despite optimized MDI or disabling hypoglycemia
- Target HbA1c ≤48 mmol/mol without problematic hypoglycemia (NICE NG17)
Type 2 Diabetes: Stepwise Intensification
- Step 1: Metformin 500 mg OD with food, titrate weekly to 1000 mg BD (max 2000 mg/day)
- Contraindicated if eGFR <30 mL/min/1.73m²
- Review at 3 months: if HbA1c remains >58 mmol/mol, add second agent
- Step 2: Dual therapy options (NICE NG28):
- SGLT2 inhibitor (empagliflozin 10-25 mg OD) if CVD/heart failure/high CV risk
- DPP-4 inhibitor (sitagliptin 100 mg OD) if hypoglycemia risk/frailty
- Sulfonylurea (gliclazide 40-160 mg BD) if cost consideration
- Pioglitazone 15-45 mg OD if SGLT2i contraindicated
- Step 3: Triple therapy or insulin initiation if HbA1c >58 mmol/mol on dual therapy
Acute Crisis Management
| Emergency | Glucose | pH | Osmolality | Fluid Deficit | Initial Fluid |
|---|---|---|---|---|---|
| DKA | >11 mmol/L | <7.3 | Normal | 5-8 L | 0.9% saline 1L/hour |
| HHS | >30 mmol/L | >7.3 | >320 mOsm/kg | 8-12 L | 0.9% saline 1L/hour initially |
DKA protocol (NICE CG155): fixed-rate IV insulin 0.1 units/kg/hour, continue SC basal insulin, add 10% dextrose when glucose <14 mmol/L. Resolution criteria: pH >7.3, ketones <0.6 mmol/L, bicarbonate >15 mmol/L.
Evidence-Based Treatment Algorithms
Differential Diagnosis: DKA, HHS, and Thyroid Emergencies
Distinguishing from other acute metabolic crises requires systematic analysis of biochemical patterns. A 68-year-old with confusion, glucose 42 mmol/L, and serum osmolality 348 mOsm/kg presents with HHS, not DKA-the absence of significant ketosis (ketones <3 mmol/L) and preserved pH (>7.3) are discriminating features. Meanwhile, can mimic or precipitate diabetic emergencies: thyrotoxic crisis causes hyperglycemia through catecholamine excess, while myxedema coma presents with hypoglycemia and hyponatremia.
Key Biochemical Discriminators
- DKA vs HHS:
- DKA: ketones >3 mmol/L, pH <7.3, bicarbonate <15 mmol/L, glucose typically 11-25 mmol/L
- HHS: ketones <3 mmol/L, pH >7.3, osmolality >320 mOsm/kg, glucose >30 mmol/L
- Overlap exists: "mixed DKA-HHS" in 30% of cases
- Mortality: HHS 15-20% vs DKA <1% (age/comorbidity-driven)
| Feature | DKA | HHS | Thyroid Storm |
|---|---|---|---|
| Onset | Hours-days | Days-weeks | Hours |
| Consciousness | Alert-drowsy | Confusion-coma common | Agitation-delirium |
| Ketones | >3 mmol/L | <3 mmol/L | Normal |
| Osmolality | <320 mOsm/kg | >320 mOsm/kg | Normal |
| Temp | Normal/hypothermic | Normal/hypothermic | Fever >39°C |
| TSH | Normal | Normal | <0.01 mU/L |
Borderline Thyroid Function Interpretation
- Subclinical hypothyroidism (TSH 4-10 mU/L, normal free T4):
- Treat if: TSH >10 mU/L on repeat, symptoms present, thyroid antibodies positive, or pregnancy
- NICE CG145: trial levothyroxine 50 mcg OD, review at 3 months
- Subclinical hyperthyroidism (TSH <0.1 mU/L, normal free T4/T3):
- Risk stratify: if age >65 years or cardiovascular disease, treat to prevent atrial fibrillation
- Radioiodine uptake scan differentiates Graves' (diffuse uptake) from nodular disease
Differential Diagnosis: DKA, HHS, and Thyroid Emergencies
Cardiovascular Risk Reduction and Individualized Therapy
NICE NG28 emphasizes that management extends beyond glycemic control to comprehensive cardiovascular risk reduction-the primary cause of mortality. The EMPA-REG and CANVAS trials demonstrated that SGLT2 inhibitors reduce major adverse cardiovascular events by 14% and heart failure hospitalizations by 35%, fundamentally shifting treatment paradigms. For patients with established CVD or CKD (eGFR <60 mL/min/1.73m²), SGLT2 inhibitors are now first-line additions to metformin, irrespective of HbA1c.
Cardiovascular Risk Stratification
- QRISK3 calculator: 10-year CVD risk >10% mandates intensive intervention
- Targets for secondary prevention ():
- Blood pressure: <140/80 mmHg (ACE inhibitor or ARB first-line)
- LDL cholesterol: <2.0 mmol/L (atorvastatin 80 mg OD)
- Antiplatelet: aspirin 75 mg OD if CVD established
- Renal protection: ACE inhibitor/ARB if ACR >3 mg/mmol, target ACR reduction >30%
Individualized HbA1c Targets
- Standard target: ≤53 mmol/mol on lifestyle + single agent
- Relaxed target: ≤59 mmol/mol if:
- High hypoglycemia risk (elderly, cognitive impairment, on sulfonylurea/insulin)
- Limited life expectancy (<5 years)
- Established complications where risks outweigh benefits
- Intensive target: ≤48 mmol/mol if newly diagnosed, motivated, no hypoglycemia
| Patient Profile | HbA1c Target | Preferred Agents | Rationale |
|---|---|---|---|
| CVD/CKD | ≤53 mmol/mol | Metformin + SGLT2i | CV/renal protection |
| Heart Failure | ≤53 mmol/mol | Metformin + SGLT2i ± GLP-1 RA | HF hospitalization reduction |
| Frail Elderly | ≤59 mmol/mol | Metformin + DPP-4i | Avoid hypoglycemia |
| Obesity (BMI >35) | ≤48 mmol/mol | Metformin + GLP-1 RA | Weight loss 5-10 kg |
⭐ Clinical Pearl: Always check eGFR before prescribing SGLT2 inhibitors-efficacy diminishes below 45 mL/min/1.73m² for glycemic control but renal/cardiac benefits persist. Warn patients about euglycemic DKA risk (rare, <0.1%) and sick day rules.
Cardiovascular Risk Reduction and Individualized Therapy
Multidisciplinary Management of Complex Endocrine Cases
A 34-year-old woman with for 15 years presents with fatigue, weight gain, and TSH 28 mU/L-autoimmune polyglandular syndrome type 3a affects 25% of Type 1 patients. Simultaneously managing insulin requirements (which decrease with levothyroxine initiation as thyroid hormone increases insulin clearance) and screening for associated conditions (celiac disease, Addison's disease) requires integrated endocrine care. reveals proliferative retinopathy requiring urgent pan-retinal photocoagulation, while management must account for pregnancy planning, as inadequately treated hypothyroidism causes fetal neurodevelopmental impairment.
Autoimmune Polyendocrine Syndromes
- Screen Type 1 diabetes patients for:
- Thyroid disease: TSH annually
- Celiac disease: tissue transglutaminase IgA at diagnosis, then if symptomatic
- Addison's disease: if unexplained hypoglycemia or electrolyte disturbance
- Pregnancy considerations:
- Levothyroxine requirements increase 30-50% in pregnancy-check TSH every 4 weeks
- Target TSH <2.5 mU/L in first trimester for fetal brain development
- Insulin requirements: decrease first trimester, increase 50-100% by third trimester
Advanced Diabetic Complications
- Proliferative retinopathy: refer ophthalmology within 2 weeks, pan-retinal photocoagulation reduces blindness risk by 50%
- Diabetic kidney disease Stage 3b+ (eGFR <45 mL/min/1.73m²):
- Adjust medications: stop metformin, reduce insulin doses (impaired clearance)
- Nephrology referral if ACR >70 mg/mmol or eGFR decline >5 mL/min/year
- Charcot foot: acute neuro-osteoarthropathy requires total contact casting, non-weight bearing
Multidisciplinary Management of Complex Endocrine Cases
High Yield Summary
Key Take-Aways:
- Type 1 diabetes: absolute insulin deficiency (C-peptide <200 pmol/L), ketosis-prone, requires immediate insulin replacement 0.6-1.0 units/kg/day
- Type 2 diabetes diagnosis: HbA1c ≥48 mmol/mol or fasting glucose ≥7.0 mmol/L; 20% have retinopathy at diagnosis
- DKA vs HHS: DKA has ketones >3 mmol/L and pH <7.3; HHS has osmolality >320 mOsm/kg and higher mortality (15-20%)
- SGLT2 inhibitors are first-line add-on to metformin for patients with CVD, CKD, or heart failure-reduce CV events by 14%
- Screen Type 1 diabetes patients annually for thyroid disease (25% develop autoimmune hypothyroidism) and celiac disease at diagnosis
- Immediate complications screening at Type 2 diagnosis: retinopathy within 3 months, ACR/eGFR, foot risk assessment
- Fixed-rate IV insulin for DKA: 0.1 units/kg/hour, add dextrose when glucose <14 mmol/L, resolution requires pH >7.3 and ketones <0.6 mmol/L
Essential Endocrinology & Diabetes Numbers:
| Parameter | Threshold | Clinical Significance |
|---|---|---|
| HbA1c Diagnosis | ≥48 mmol/mol | Diabetes confirmed |
| DKA Ketones | >3 mmol/L | Diagnostic for DKA |
| HHS Osmolality | >320 mOsm/kg | Diagnostic for HHS |
| TSH (Hypothyroidism) | >10 mU/L | Overt disease, treat |
| ACR (Nephropathy) | >3 mg/mmol | Diabetic kidney disease |
| Metformin Contraindication | eGFR <30 mL/min/1.73m² | Stop metformin |
Key Principles/Pearls:
- Always continue basal insulin during DKA treatment-stopping causes rebound ketogenesis
- Levothyroxine increases insulin clearance; expect 10-20% insulin dose increase when treating hypothyroidism in Type 1 diabetes
- HHS mortality is 10-fold higher than DKA despite less dramatic biochemistry-aggressive fluid resuscitation (8-12 L deficit) is critical
- SGLT2 inhibitors lose glycemic efficacy below eGFR 45 mL/min/1.73m² but retain cardiovascular/renal benefits-don't stop
- Screen for retinopathy within 3 months of Type 2 diagnosis, not at diagnosis-allows time for glycemic optimization before assessment
Quick Reference:
| Emergency | Glucose | pH | Ketones | Osmolality | Initial Fluid | Insulin Rate |
|---|---|---|---|---|---|---|
| DKA | >11 mmol/L | <7.3 | >3 mmol/L | <320 | 1L 0.9% saline/hour | 0.1 units/kg/hour |
| HHS | >30 mmol/L | >7.3 | <3 mmol/L | >320 | 1L 0.9% saline/hour | 0.05 units/kg/hour |
Practice Questions: Endocrinology & Diabetes
Test your understanding with these related questions
A 42-year-old woman presents with fatigue, muscle aches, and widespread pain. She has multiple tender points but normal inflammatory markers. Sleep is poor. What is the most appropriate initial treatment?
Flashcards: Endocrinology & Diabetes
Enjoying this lesson?
Get full access to all lessons, practice questions, and more.
Start Your Free Trial